Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 172,262	$ 29	$ 318,574	$ 313	$ (146,654)
Beginning balance, shares at Dec. 31, 2020		29,543,222
Exercise of stock options	1,113	$ 1	1,112
Exercise of stock options, shares		112,564
Stock based compensation	13,741		13,741
Foreign currency translation adjustments	0
Other comprehensive loss	(196)			(196)
Net loss	(44,840)				(44,840)
Ending balance at Jun. 30, 2021	142,080	$ 30	333,427	117	(191,494)
Ending balance, shares at Jun. 30, 2021		29,655,786
Beginning balance at Mar. 31, 2021	156,484	$ 29	326,006	189	(169,740)
Beginning balance, shares at Mar. 31, 2021		29,575,944
Exercise of stock options	672	$ 1	671
Exercise of stock options, shares		79,842
Stock based compensation	6,750		6,750
Foreign currency translation adjustments	0
Other comprehensive loss	(72)			(72)
Net loss	(21,754)				(21,754)
Ending balance at Jun. 30, 2021	142,080	$ 30	333,427	117	(191,494)
Ending balance, shares at Jun. 30, 2021		29,655,786
Beginning balance at Dec. 31, 2021	118,586	$ 30	355,234	(79)	(236,599)
Beginning balance, shares at Dec. 31, 2021		30,074,412
Issuance of common stock in connection with open market sales agreement, net of issuance costs	608		608
Issuance of common stock in connection with open market sales agreement, net of issuance costs, shares		51,769
Issuance of common stock on exercise of stock options and vesting of restricted stock units	134		134
Issuance of common stock on exercise of stock options and vesting of restricted stock units, shares		331,507
Stock based compensation	14,292		14,292
Value of share Issued in connection with acquisition of Novosteo	16,504	$ 6	16,498
Share issuance in connection with acquisition of Novosteo Inc.		5,520,000
Foreign currency translation adjustments	137			137
Other comprehensive loss	(524)			(524)
Net loss	(38,205)				(38,205)
Ending balance at Jun. 30, 2022	111,532	$ 36	386,766	(466)	(274,804)
Ending balance, shares at Jun. 30, 2022		35,977,688
Beginning balance at Mar. 31, 2022	106,380	$ 30	365,096	(506)	(258,240)
Beginning balance, shares at Mar. 31, 2022		30,149,570
Issuance of common stock on exercise of stock options and vesting of restricted stock units	121		121
Issuance of common stock on exercise of stock options and vesting of restricted stock units, shares		308,118
Stock based compensation	5,051		5,051
Value of share Issued in connection with acquisition of Novosteo	16,504	$ 6	16,498
Share issuance in connection with acquisition of Novosteo Inc.		5,520,000
Foreign currency translation adjustments	250			250
Other comprehensive loss	(210)			(210)
Net loss	(16,564)				(16,564)
Ending balance at Jun. 30, 2022	$ 111,532	$ 36	$ 386,766	$ (466)	$ (274,804)
Ending balance, shares at Jun. 30, 2022		35,977,688